John E. Bishop - 14 Oct 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.

Role: SVP, Chief Technology Officer
Signature: /s/ Jeannette Potts, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Oct 2022
Net transactions value: $0
Form type: 4
Filing time: 14 Oct 2022, 16:06:49 UTC
Previous filing: 02 Mar 2022
Next filing: 28 Feb 2023
SEC: View on sec.gov

Quoteable Key Fact

"John E. Bishop filed Form 4 for Forma Therapeutics Holdings, Inc. on 14 Oct 2022."

Quick Takeaways

This page summarizes John E. Bishop's Form 4 filing for Forma Therapeutics Holdings, Inc..
3 reported transactions and 2 derivative rows are listed below.
Filing timestamp: 14 Oct 2022, 16:06.

What Changed

Previous filing in this sequence was filed on 02 Mar 2022.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FMTX	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction		-47,950	-100%		0	14 Oct 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FMTX	Stock Option (Right to Buy)	Disposed to Issuer		-67,000	-100%		0	14 Oct 2022	Common Stock	67,000	$24.26	Direct	F1, F3
transaction	FMTX	Stock Option (Right to Buy)	Disposed to Issuer		-38,930	-100%		0	14 Oct 2022	Common Stock	38,930	$9.86	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John E. Bishop is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.
F2	Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
F3	Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.